Abnormal APP processing in platelets of patients with Alzheimer's disease: Correlations with membrane fluidity and cognitive decline

Psychopharmacology

Volumn 192, Issue 4, 2007, Pages 547-553

  Zainaghi, Isis A ^a   Forlenza, Orestes V ^a   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Alzheimer's disease; APP ratio; Membrane fluidity; Mild cognitive impairment; Platelet; Western blot APP

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; AMYLOID PRECURSOR PROTEIN;

AGED; ALZHEIMER DISEASE; ANISOTROPY; ARTICLE; CAMBRIDGE COGNITIVE TEST; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEMBRANE FLUIDITY; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; THROMBOCYTE; WESTERN BLOTTING;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BIOLOGICAL MARKERS; BLOOD PLATELETS; BLOTTING, WESTERN; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMBRANE FLUIDITY; PEPTIDE FRAGMENTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 34249909779     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0748-5     Document Type: Article

References (44)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
2. Army Individual Test Battery (1944) Manual of directions and scoring war department, Adjunt General's Office Trail, Washington
3. Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM (2000) Platelet APP isoform ratios correlated with declining cognition in AD. Neurology 54:1907-1909
4. Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114:797-811
5. Daly IVJ, Lahiri DK, Justus DE, Kotwal GJ (1998) Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain. Life Sci 63:2121-2131
6. Davies TA, Long HJ, Sgro K, Rathbun WH, Mcmenamin ME, Seetoo K, Tibbles H, Billingslea AM, Fine RE, Fishman JB, Levesque CA, Smith SJ, Wells JM, Simons ER (1997) Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiol Aging 18:147-153
7. Di Luca M, Pastorino L, Cattabeni F, Zanardi R, Scarone S, Racagni G, Smeraldi E, Perez J (1996) Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol 53:1162-1166
8. Di Luca M, Pastorino L, Bianchetti A, Perez J, Viagnolo LA, Lenzi GL, Trabucchi M, Cattebeni F, Padovani A (1998) Differential level of platelet amyloid β precursor protein isoforms-an early marker for Alzheimer disease. Arch Neurol 55:1195-1200
9. Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F (2000) Platelets as a peripheral district were to study pathogenetic mechanisms of Alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol 405:277-283
10. Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE (2000) Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement Geriatr Cogn Disord 11(4):181-186
11. Erzigkeit H (1991) The development of the SKT project. In: Hindmarch I, Hippius H, Wilcock GK (eds) Dementia: molecules, methods and measures. Wiley, Chichester, England, pp 101-108
12. Fernandes MAS, Proença MT, Nogueira AJA, Oliveira LMV, Santiago B, Santana I, Oliveira CR (1999) Effects of apolipoprotein E genotype on blood lipid composition and membrane platelet fluidity in Alzheimer's disease. Biochim Biophys Acta 1454:89-96
13. Flaks MK, Yassuda MS, Regina ACB, Cid AG, Camargo CHP, Gattaz WF, Forlenza OV (2006) The short test (SKT)-a transcultural test for early detection and discrimination of dementia: a preliminary study in Brazil. Int Psychogeriatr 18:121-133
14. Folstein MF, Folstein SE, Mchugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
15. Fuld P (1980) Guaranteed stimulus processing in the evaluation of memory and learning. Cortex 16:255-271
16. Haass C (2004) Take five-Bace and the γ-secretase quartet conduct Alzheimer's amyloid β-peptide generation. EMBO J 23:483-488
17. Hachinski VC, Iliff ID, Zihkla E, Du Boulay GH, McAllister VL, Marshall J, Russel RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632-637
18. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
19. 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9:705-710
20. Hansson O, Zetterberg H, Buchhave P, Londos L, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228-234
21. Jorm AF, Jacomb PA (1989) The informant questionnaire on cognitive decline in the elderly: sociodemographics correlates, reliability, validity and some norms. Psychol Med 19:1015-1022
22. Kukull WA, Hinds TR, Schellenberg GD, Belle Gv, Larson EB (1992) Increased platelet membrane fluidity as a diagnostic marker for Alzheimer's disease. Neurology 42:607-614
23. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL (1998) Secretion of Alzheimer's disease Aβ amyloid peptide by activated human platelets. Lab Invest 78:461-469
24. 1-42 levels in the mild cognitive impairment stage of Alzheimer's disease. Exp Neurol 172:433-439
25. Mc Khann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer disease: report of NINCDS-ADRDA work group under the auspices of Department of Health and Human Service Task Force on Alzheimer disease. Neurology 34:939-944
26. Müller WE, Kock S, Eckert A, Hartmann H, Scheuer K (1995) β-amyloid peptide decreases membrane fluidity. Brain Res 674:133-136
27. Müller WE, Koch S, Scheur K, Rostock A, Bartsch R (1997) Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol 53(2):135-140
28. Oliveira R, Schmidt SL (1999) Teste Comportamental de Memória de Rivermead. Cognição, Rio de Janeiro
29. Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, Lenzi GL, Caltagirone C, Trabucchi M, Cattabeni F, Di Luca M (2002) Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol 59:71-75
30. Petersen RC (2005) Mild cognitive impairment: useful or not? Alzheimer's Dement 1:5-10
31. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303-308
32. Racchi M, Govoni S (2003) The pharmacology of amyloid precursor protein processing. Exp Gerontol 38:145-157
33. Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullun MC, Weiner MF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54:139-144
34. Roth M, Hopkins B (1953) Psychological test performance in patients over 60. I. Senile psychosis and affective disorders of old age. J Ment Sci 99:439-450
35. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX: a standardized instrument for the diagnosis of mental disorders in the elderly with special reference to early detection of dementia. Br J Psychiatry 149:698-709
36. Skovronsky DM, Lee VMY, Praticò D (2001) Amyloid precursor protein and amyloid β peptide in human platelet. J Biol Chem 276:17036-17043
37. Sunderland T, Hill Jl, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH (1989) Clock drawing in Alzheimer's disease. A novel measure of disease severity. J Am Geriatr Soc 37:725-729
38. Tang K, Hynan LS, Baskin F, Rosenberg RN (2006) Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci 240:53-58
39. Wechsler DI (1981) Examiner's manual: Wechsler adult intelligence scale-revised. Psychological Corporation, New York
40. Wilson B, Cockburn J, Baddeley AD (1985) Rivermead behavioural memory test. Thames Valley, Suffolk
41. Wood WG, Eckert GP, Igbavboa U, Müller WE (2003) Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochimica et Biophysica Acta 1610(2):281-290
42. Zubenko GS, Malinakova I, Chojnacki B (1987a) Proliferation of internal membranes in platelets from patients with Alzheimer's disease. J Neuropathol Exp Neurol 46:407-418
43. Zubenko GS, Wusylko M, Cohen BM, Boller F, Teply I (1987b) Family study of platelet membrane fluidity in Alzheimer disease. Science 238:539-542
44. Zubenko GS, Kopp U, Seto T, Firestone LL (1999) Platelet membrane fluidity individuals at risk for Alzheimer's disease: a comparison of results from fluorescence spectroscopy and electron spin resonance spectroscopy. Psychopharmacology 145:175-180